You can buy or sell IsoRay and other stocks, options, ETFs, and crypto commission-free!
IsoRay, Inc., also called IsoRay, is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Read More Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.
52 Week High
52 Week Low
Yahoo FinanceMay 23
Imagine Owning IsoRay And Trying To Stomach The 81% Share Price Drop
IsoRay, Inc. (NYSEMKT:ISR) shareholders should be happy to see the share price up 19% in the last quarter. But will that repair the damage for the weary investors who have owned this stock as it declined over half a decade? Probably not. Indeed, the share price is down a whopping 81% in that time. So we don't gain too much confidence from the recent recovery. The real question is whether the business can leave its past behind and improve itself over the years ahead. While a drop like that is definitely a b...
Yahoo FinanceMay 9
IsoRay Reports Q3 Loss, Tops Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 0.21%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Yahoo FinanceMay 9
IsoRay: Fiscal 3Q Earnings Snapshot
RICHLAND, Wash. (AP) _ IsoRay Inc. (ISR) on Thursday reported a loss of $1.1 million in its fiscal third quarter. On a per-share basis, the Richland, Washington-based company said it had a loss of 2 cents. The isotope-based medical products maker posted revenue of $1.9 million in the period. In the final minutes of trading on Thursday, the company's shares hit 43 cents. A year ago, they were trading at 39 cents. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) usin...
Expected Sep 24, After Hours